ArticleOncology reports2022

Dual STAT‑3 and IL‑6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL‑6/IL‑6R/STAT‑3 axis.

Anibal Méndez-Clemente et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.